Skip to main content
CORESTEMCHEMON Inc. logo

CORESTEMCHEMON Inc. — Investor Relations & Filings

Ticker · 166480 ISIN · KR7166480004 KO Professional, scientific and technical activities
Open in API
Filings indexed 274 across all filing types
Latest filing 2024-03-14 AGM Information
Country KR South Korea
Listing KO 166480

About CORESTEMCHEMON Inc.

https://www.corestemchemon.com/eng/main…

CORESTEMCHEMON Inc. is a biotechnology company operating through two main divisions: a biopharmaceutical unit and a non-clinical Contract Research Organization (CRO) unit. The biopharmaceutical division is dedicated to the research and development of new drugs based on stem cell therapy technology. Its clinical pipeline primarily targets neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), cerebellar ataxia, and multiple sclerosis, as well as autoimmune diseases like systemic lupus erythematosus (SLE) and fibrosis. The non-clinical CRO division provides comprehensive preclinical services, conducting essential toxicity and efficacy evaluations for pharmaceuticals, biopharmaceuticals, cosmetics, and medical devices to support regulatory approval processes.

Recent filings

Filing Released Lang Actions
주주총회집중일개최사유신고
AGM Information Classification · 1% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company scheduled its AGM on a date designated as a 'concentrated date' by the KOSDAQ Association, citing audit schedules and operational preparation. Since this is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or a report publication announcement, it falls under the general regulatory filing category.
2024-03-14 Korean
교환청구권행사
Capital/Financing Update Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) regarding the exercise of exchange rights (교환청구권행사) for exchangeable bonds. It details the number of shares issued, the conversion price, and the remaining balance of the bonds. This type of disclosure regarding capital structure changes and the conversion of debt into equity falls under the 'Share Issue/Capital Change' category.
2024-03-14 Korean
주주총회소집결의
AGM Information Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Corestemchemone. It outlines the date, location, and agenda items (such as approval of financial statements and director compensation) for the upcoming Annual General Meeting. This document serves as the official proxy solicitation and meeting notice provided to shareholders to inform them of the meeting and the matters to be voted upon.
2024-02-29 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (Corestemchemone) announcing a significant change (over 30%) in revenue or profit structure. This is a standard disclosure requirement for publicly traded companies in Korea (often referred to as a 'Fair Disclosure' or 'Significant Change' filing). Since it provides key financial highlights and performance metrics for the fiscal year, it falls under the 'Earnings Release' category as it serves as the initial announcement of financial results before the full audit is finalized. FY 2023
2024-02-28 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is specifically used to report changes in share ownership by company insiders (directors/executives). According to the provided definitions, reports of personal share transactions by company directors and executives are classified as 'Director's Dealing' (DIRS).
2024-01-03 Korean
투자판단관련주요경영사항(임상시험계획승인신청)(항아쿠아포린4 항체 양성 시신경척수염 범주질환 환자에서 동종골수유래 중간엽줄기세포와 면역억제제의 병용 치료 시 안전성 및 내약성을 평가하기 위한 1상 임상시험 계획 승인 신청)
Regulatory Filings Classification · 1% confidence The document is a regulatory filing from a Korean company (Corestemchemone) regarding the submission of a clinical trial plan (IND) to the Ministry of Food and Drug Safety (MFDS). It details the trial name, purpose, methodology, and regulatory status. Since it is a formal regulatory disclosure of a material business event (clinical trial application) and does not fit into specific categories like financial reports or shareholder meetings, it is classified as a Regulatory Filing (RNS).
2023-12-26 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.